Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06131489

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Met HLH-2004 diagnostic criteria;
  • EBV-DNA in the peripheral blood > 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues;
  • Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;
  • Age >18 years old, gender is not limited;
  • Estimated survival time > 1 month;
  • Informed consent obtained.

Exclusion criteria

  • Active infections (viral, bacterial, fungal or parasitic);
  • Diagosed with malignant tumos within 5 years;
  • Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;
  • Heart function above grade II (NYHA);
  • Severe myocardial injury:TNT、TNI、CK-MB > 3 ULN;
  • Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease;
  • Pregnancy or lactating Women;
  • Allergic to pegylated liposomal doxorubicin and etoposide;
  • HIV antibody positivity;
  • Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);
  • Participate in other clinical research at the same time;
  • The researchers considered that patients are not suitable for the study.

Treatment and study plan

Segmental bowel resection combined with the DEP regimen

Other

Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles

Primary outcomes

  1. ORR

    Time frame: 4 Week

    The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.

  2. Adverse events

    Time frame: 1 month

    Incidence of adverse reactions

Secondary outcomes

  1. OS

    Time frame: 1 years

    Overall survival rate

Study contacts

Contact information is provided by the study sponsor or research team.

Zhao Wang, MD

CONTACT

[email protected]

63138303

Sponsors and collaborators

Lead sponsor

Beijing Friendship Hospital

Other

Registry information

Official study title

Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Nov 14, 2023
Registry last updated
Nov 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.